Cardinal Health (CAH) 10-Q 4 May 23 2023 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Mar. 31, 2023	Apr. 30, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	1-11373
Entity Registrant Name	Cardinal Health, Inc.
Entity Central Index Key	0000721371
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Incorporation, State or Country Code	OH
Entity Tax Identification Number	31-0958666
Entity Address, Address Line One	7000 Cardinal Place
Entity Address, City or Town	Dublin
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	43017
City Area Code	614
Local Phone Number	757-5000
Title of 12(b) Security	Common shares (without par value)
Trading Symbol	CAH
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		254,600,182

Condensed Consolidated Statemen

Condensed Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenue	$ 50,487	$ 44,836	$ 151,559	$ 134,261
Cost of products sold	48,702	43,154	146,497	129,321
Gross margin	1,785	1,682	5,062	4,940
Operating expenses:
Distribution, selling, general and administrative expenses	1,179	1,137	3,567	3,402
Restructuring and employee severance	16	31	62	56
Amortization and other acquisition-related costs	74	79	216	237
Impairments and (gain)/loss on disposal of assets, net	20	471	883	1,764
Litigation (recoveries)/charges, net	(76)	61	(256)	113
Operating earnings/(loss)	572	(97)	590	(632)
Other (income)/expense, net	0	3	(5)	(14)
Interest expense, net	28	38	78	115
Loss on early extinguishment of debt	0	0	0	10
(Gain)/loss on sale of equity interest in naviHealth	0	(1)	0	(2)
Earnings/(loss) before income taxes	544	(137)	517	(741)
Provision for income taxes	197	1,253	189	328
Net earnings/(loss)	347	(1,390)	328	(1,069)
Less: Net earnings attributable to noncontrolling interests	(2)	(1)	(3)	(2)
Net earnings/(loss) attributable to Cardinal Health, Inc.	$ 345	$ (1,391)	$ 325	$ (1,071)
Earnings/(Loss) per common share attributable to Cardinal Health, Inc.:
Basic (in shares)	$ 1.35	$ (5.05)	$ 1.24	$ (3.82)
Diluted (in shares)	$ 1.34	$ (5.05)	$ 1.23	$ (3.82)
Weighted-average number of common shares outstanding:
Basic (in shares)	256	275	263	281
Diluted (in shares)	258	275	264	281
Cash dividends declared per common share	$ 0.4957	$ 0.4908	$ 1.4871	$ 1.4724

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Net earnings/(loss)	$ 347	$ (1,390)	$ 328	$ (1,069)
Other comprehensive income/(loss):
Foreign currency translation adjustments and other	4	(4)	(34)	(47)
Net unrealized gain on derivative instruments, net of tax	0	12	6	4
Total other comprehensive income/(loss), net of tax	4	8	(28)	(43)
Total comprehensive income/(loss)	351	(1,382)	300	(1,112)
Less: Net earnings attributable to noncontrolling interests	(2)	(1)	(3)	(2)
Total comprehensive income attributable to Cardinal Health, Inc.	$ 349	$ (1,383)	$ 297	$ (1,114)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) shares in Thousands, $ in Millions	Mar. 31, 2023	Jun. 30, 2022
Current assets:
Cash and equivalents	$ 3,990	$ 4,717
Trade receivables, net	10,992	10,561
Inventories, net	16,620	15,636
Prepaid expenses and other	1,895	2,021
Total current assets	33,497	32,935
Property and equipment, net	2,362	2,361
Goodwill and other intangibles, net	6,567	7,629
Other assets	951	953
Total assets	43,377	43,878
Current liabilities:
Accounts payable	29,601	27,128
Current portion of long-term obligations and other short-term borrowings	26	580
Other accrued liabilities	2,876	2,842
Total current liabilities	32,503	30,550
Long-term obligations, less current portion	4,708	4,735
Deferred income taxes and other liabilities	8,384	9,299
Preferred shares, without par value:
Authorized—500 thousand shares, Issued—none	0	0
Common shares, without par value:
Authorized—755 million shares, Issued—327 million shares at March 31, 2023 and June 30, 2022	2,818	2,813
Accumulated deficit	(342)	(280)
Common shares in treasury, at cost: 72 million shares and 54 million shares at March 31, 2023 and June 30, 2022, respectively	(4,554)	(3,128)
Accumulated other comprehensive loss	(142)	(114)
Total Cardinal Health, Inc. shareholders' deficit	(2,220)	(709)
Noncontrolling interests	2	3
Total shareholders’ deficit	(2,218)	(706)
Total liabilities and shareholders’ deficit	$ 43,377	$ 43,878
Preferred shares, authorized	500	500
Preferred shares, issued	0	0
Common shares, authorized	755,000	755,000
Common shares, issued	327,000	327,000
Common shares in treasury	72,000	54,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - shares shares in Thousands	Mar. 31, 2023	Jun. 30, 2022
Statement of Financial Position [Abstract]
Preferred shares, authorized	500	500
Preferred shares, issued	0	0
Common shares, authorized	755,000	755,000
Common shares, issued	327,000	327,000
Common shares in treasury	72,000	54,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Millions	Total	Common Stock	Retained Earnings	Treasury Stock, Common	Accumulated Other Comprehensive Income/(Loss)	Noncontrolling Interest
Common shares in treasury				36,000
Balance at beginning of period (in shares) at Jun. 30, 2021		327,000
Balance at beginning of period at Jun. 30, 2021	$ 1,794	$ 2,806	$ 1,205		$ (34)	$ 3
Treasury, balance at beginning of period (in shares) at Jun. 30, 2021				(36,000)
Treasury, balance at beginning of period at Jun. 30, 2021				$ (2,186)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	(1,069)					2
Net Income (Loss) Attributable to Parent	(1,071)
Other Comprehensive Income (Loss), Net of Tax	(43)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(43)				(43)
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		0		1,000
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	41	$ (5)		$ 46
Purchase of treasury shares	(1,000)	$ 40		$ (1,000)
Treasury shares acquired (in shares)				(19,000)
Dividends	(415)		(415)
Stockholders' Equity, Other Shares
Other	1					1
Balance at end of period (in shares) at Mar. 31, 2022		327,000
Balance at end of period at Mar. 31, 2022	(693)	$ 2,761	(281)		(77)	4
Treasury, balance at end of period (in shares) at Mar. 31, 2022				(54,000)
Treasury, balance at end of period at Mar. 31, 2022				$ (3,100)
Treasury Stock, Value, Acquired, Cost Method	(1,000)			$ (960)
Common shares in treasury				50,000
Balance at beginning of period (in shares) at Dec. 31, 2021		327,000
Balance at beginning of period at Dec. 31, 2021	1,002	$ 2,721	1,245		(85)	4
Treasury, balance at beginning of period (in shares) at Dec. 31, 2021				(50,000)
Treasury, balance at beginning of period at Dec. 31, 2021				$ (2,883)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	(1,390)					1
Net Income (Loss) Attributable to Parent	(1,391)
Other Comprehensive Income (Loss), Net of Tax	8
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	8				8
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		0
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	23	$ 20		$ 3
Purchase of treasury shares		(20)
Treasury shares acquired (in shares)				(4,000)
Dividends	(135)		(135)
Stockholders' Equity, Other Shares
Other	1					1
Balance at end of period (in shares) at Mar. 31, 2022		327,000
Balance at end of period at Mar. 31, 2022	(693)	$ 2,761	(281)		(77)	4
Treasury, balance at end of period (in shares) at Mar. 31, 2022				(54,000)
Treasury, balance at end of period at Mar. 31, 2022				$ (3,100)
Treasury Stock, Value, Acquired, Cost Method	$ (200)			$ (220)
Common shares in treasury				54,000
Common shares in treasury	54,000			(54,000)
Balance at beginning of period (in shares) at Jun. 30, 2022	327,000	327,000
Balance at beginning of period at Jun. 30, 2022	$ (706)	$ 2,813	(280)		(114)	3
Treasury, balance at beginning of period (in shares) at Jun. 30, 2022	(54,000)			54,000
Treasury, balance at beginning of period at Jun. 30, 2022	$ (3,128)			$ 3,128
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	328					3
Net Income (Loss) Attributable to Parent	325
Other Comprehensive Income (Loss), Net of Tax	(28)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	$ (28)				(28)
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture	2,000
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	$ 82	$ 5		77
Purchase of treasury shares	(1,500)			$ (1,500)
Treasury shares acquired (in shares)				(20,000)
Dividends	(388)		(388)
Stockholders' Equity, Other Shares
Other	$ 1		(1)			2
Balance at end of period (in shares) at Mar. 31, 2023	327,000	327,000
Balance at end of period at Mar. 31, 2023	$ (2,218)	$ 2,818	(342)		(142)	2
Treasury, balance at end of period (in shares) at Mar. 31, 2023	(72,000)			(72,000)
Treasury, balance at end of period at Mar. 31, 2023	$ (4,554)			$ (4,554)
Treasury Stock, Value, Acquired, Cost Method	(1,503)			$ (1,503)
Treasury shares acquired, average price per share (in usd per share)	(2)					(2)
Common shares in treasury				(68,000)
Balance at beginning of period (in shares) at Dec. 31, 2022		327,000
Balance at beginning of period at Dec. 31, 2022	(2,212)	$ 2,747	(560)		(146)	1
Treasury, balance at beginning of period (in shares) at Dec. 31, 2022				68,000
Treasury, balance at beginning of period at Dec. 31, 2022				$ 4,254
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	347					2
Net Income (Loss) Attributable to Parent	345
Other Comprehensive Income (Loss), Net of Tax	4
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	4
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		0		0
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	24	$ 21		$ 3
Purchase of treasury shares		(50)
Treasury shares acquired (in shares)				(4,000)
Dividends	(128)		(128)
Stockholders' Equity, Other Shares
Other	$ 0		1			(1)
Balance at end of period (in shares) at Mar. 31, 2023	327,000	327,000
Balance at end of period at Mar. 31, 2023	$ (2,218)	$ 2,818	$ (342)		$ (142)	$ 2
Treasury, balance at end of period (in shares) at Mar. 31, 2023	(72,000)			(72,000)
Treasury, balance at end of period at Mar. 31, 2023	$ (4,554)			$ (4,554)
Treasury Stock, Value, Acquired, Cost Method	$ (253)			$ (303)
Common shares in treasury	72,000			72,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net earnings/(loss)	$ 328	$ (1,069)
Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:
Depreciation and amortization	516	513
Impairments and (gain)/loss on disposal of assets, net	883	1,764
Impairments and loss on sale of other investments	0	3
(Gain)/loss on sale of equity interest in naviHealth	0	(2)
Loss on early extinguishment of debt	0	10
Share-based compensation	69	65
Provision for bad debts	79	46
Change in operating assets and liabilities, net of effects from acquisitions and divestitures:
Increase in trade receivables	(510)	(1,193)
Increase in inventories	(1,012)	(922)
Increase in accounts payable	2,473	1,121
Other accrued liabilities and operating items, net	(845)	(206)
Net cash provided by operating activities	1,981	130
Cash flows from investing activities:
Proceeds from divestitures, net of cash sold	0	923
Acquisition of subsidiaries, net of cash acquired	10	0
Additions to property and equipment	(264)	(223)
Proceeds from disposal of property and equipment	2	11
Purchases of investments	(6)	(38)
Proceeds from investments	1	27
Proceeds from net investment hedge terminations	29	71
Net cash provided by/(used in) investing activities	(248)	771
Cash flows from financing activities:
Reduction of long-term obligations	(571)	(597)
Net tax proceeds/(withholdings) from share-based compensation	11	(26)
Dividends on common shares	(399)	(425)
Purchase of treasury shares	(1,500)	(1,000)
Net cash used in financing activities	(2,459)	(2,048)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations	(1)	(13)
Cash and equivalents reclassified from/(to) assets held for sale	0	109
Net decrease in cash and equivalents	(727)	(1,051)
Cash and equivalents at beginning of period	4,717	3,407
Cash and equivalents at end of period	$ 3,990	$ 2,356

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	1. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively. References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2023 and June 30, 2022, respectively. Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (our "2022 Form 10-K"). Recently Issued Financial Accounting Standards Not Yet Adopted We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements. Recently Adopted Financial Accounting Standards There were no new material accounting standards adopted during the nine months ended March 31, 2023.

Divestitures

Divestitures	9 Months Ended
	Mar. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations, Disclosure	2. Divestitures In August 2021, we sold the Cordis business to Hellman & Friedman for proceeds of $923 million, net of cash transferred, and we retained certain working capital accounts. Cardinal Health also retained product liability associated with lawsuits and claims related to the Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products in the U.S. and Canada, as well as authority for these matters discussed in Note 6 . The Cordis business operated within our Medical segment.

Restructuring and Employee Seve

Restructuring and Employee Severance	9 Months Ended
	Mar. 31, 2023
Restructuring Charges [Abstract]
Restructuring and Employee Severance	3. Restructuring and Employee Severance The following table summarizes restructuring and employee severance: Three Months Ended March 31, (in millions) 2023 2022 Employee-related $ 3 $ 12 Facility exit and other 13 19 Total restructuring and employee severance $ 16 $ 31 Nine Months Ended March 31, (in millions) 2023 2022 Employee-related $ 32 $ 22 Facility exit and other 30 34 Total restructuring and employee severance $ 62 $ 56 Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of project consulting fees, accelerated depreciation, professional, project management and other service fees to support divestitures, costs associated with vacant facilities, and certain other divestiture-related costs. Restructuring and employee severance costs during the three and nine months ended March 31, 2023 and March 31, 2022 were primarily related to the implementation of certain enterprise-wide cost-savings measures and the divestiture of the Cordis business. During the three and nine months ended March 31, 2022, restructuring also included costs related to decreasing our overall office space. The following table summarizes activity related to liabilities associated with restructuring and employee severance: (in millions) Employee- Facility Exit Total Balance at June 30, 2022 $ 56 $ 10 $ 66 Additions 29 8 37 Payments and other adjustments (36) (15) (51) Balance at March 31, 2023 $ 49 $ 3 $ 52

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	9 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	4. Goodwill and Other Intangible Assets Goodwill The following table summarizes the changes in the carrying amount of goodwill by segment and in total: (in millions) Pharmaceutical Medical (1) Total Balance at June 30, 2022 $ 2,673 $ 3,182 $ 5,855 Goodwill acquired, net of purchase price adjustments — 13 13 Foreign currency translation adjustments and other — (5) (5) Goodwill impairment — (863) (863) Balance at March 31, 2023 $ 2,673 $ 2,327 $ 5,000 (1) At March 31, 2023 and June 30, 2022, the Medical segment accumulated goodwill impairment loss was $4.4 billion and $3.5 billion, respectively. Due to changes in our long-term financial plan assumptions made during the three months ended March 31, 2023, we elected to bypass the qualitative assessment and perform quantitative goodwill impairment testing for the Medical Unit. The fair value of the reporting unit was estimated to be approximately 4 percent in excess of its carrying value, primarily driven by a lower discount rate as described below. We performed quantitative goodwill impairment testing for the Medical Unit at December 31, 2022 and September 30, 2022, which resulted in pre-tax goodwill impairment charges of $709 million and $154 million, respectively. The impairment charge recognized in the second quarter was driven by certain reductions in our long-term financial plan assumptions, and the impairment charge recognized in the first quarter was driven by an increase in the discount rate primarily due to an increase in the risk-free interest rate. The cumulative pre-tax goodwill impairment charges of $863 million were recognized in impairments and (gain)/loss on disposal of assets, net in our condensed consolidated statements of earnings/(loss) for the nine months ended March 31, 2023. Our determinations of the estimated fair value of the Medical Unit at March 31, 2023, December 31, 2022 and September 30, 2022 were based on a combination of the income-based approach (using a terminal growth rate of 2 percent), and the market-based approaches. For the income-based approach, we used discount rates of 10 percent, 10.5 percent and 10.5 percent for each quarter, respectively. The decrease in the discount rate for the interim testing performed at March 31, 2023 was primarily due to a decrease in the risk-free interest rate. Additionally, we assigned a weighting of 80 percent to the discounted cash flow method, 10 percent to the guideline public company method, and 10 percent to the guideline transaction method. Our fair value estimates utilize significant unobservable inputs and thus represent Level 3 fair value measurements. During the three months ended March 31, 2022 and December 31, 2021, we performed quantitative goodwill impairment testing for the Medical Unit. This quantitative testing resulted in the carrying amount of the Medical Unit exceeding the fair value, resulting in a pre-tax impairment charges of $474 million and $1.3 billion recorded during the three months ended March 31, 2022 and December 31, 2021, respectively. Other Intangible Assets The following tables summarize other intangible assets by class at: March 31, 2023 (in millions) Gross Accumulated Net Weighted- Average Remaining Amortization Period (Years) Indefinite-life intangibles: Trademarks and patents $ 11 $ — $ 11 N/A Total indefinite-life intangibles 11 — 11 N/A Definite-life intangibles: Customer relationships 3,235 2,267 968 10 Trademarks, trade names and patents 550 376 174 9 Developed technology and other 1,037 623 414 9 Total definite-life intangibles 4,822 3,266 1,556 10 Total other intangible assets $ 4,833 $ 3,266 $ 1,567 N/A June 30, 2022 (in millions) Gross Accumulated Net Indefinite-life intangibles: Trademarks and patents $ 11 $ — $ 11 Total indefinite-life intangibles 11 — 11 Definite-life intangibles: Customer relationships 3,272 2,165 1,107 Trademarks, trade names and patents 552 360 192 Developed technology and other 1,038 574 464 Total definite-life intangibles 4,862 3,099 1,763 Total other intangible assets $ 4,873 $ 3,099 $ 1,774

Long-Term Obligations and Other

Long-Term Obligations and Other Short-Term Borrowings	9 Months Ended
	Mar. 31, 2023
Long-Term Obligations and Other Short-Term Borrowings [Abstract]
Long-Term Obligations and Other Short-Term Borrowings	5. Long-Term Obligations and Other Short-Term Borrowings Long-Term Debt We had total long-term obligations, including the current portion and other short-term borrowings, of $4.7 billion and $5.3 billion for March 31, 2023 and June 30, 2022, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These notes are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $29.6 billion and $27.1 billion at March 31, 2023 and June 30, 2022, respectively. During the three months ended March 31, 2023, we repaid the full principal of the $550 million 3.2% Notes due 2023 at maturity with available cash. During the nine months ended March 31, 2022, we redeemed all outstanding $572 million principal amount of 2.616% Notes due June 2022 at a redemption price equal to 100% of the principal amount and accrued but unpaid interest, plus the make-whole premium applicable to the notes. In connection with this redemption, we recorded a $10 million loss on early extinguishment of debt. The early redemption was funded with available cash. Other Financing Arrangements In addition to cash and equivalents and operating cash flow, other sources of liquidity include a $2.0 billion commercial paper program backed by a $2.0 billion revolving credit facility. We also have a $1.0 billion committed receivables sales facility. During the nine months ended March 31, 2023, under our commercial paper program and our committed receivables program, we had maximum combined total daily amounts outstanding of $445 million and average combined daily amount outstanding of $4 million. At March 31, 2023, we had no amounts outstanding under our commercial paper program, revolving credit facility or our committed receivables sales facility. In February 2023, we extended our $2.0 billion revolving credit facility through February 25, 2028. In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2025. CHF was organized for the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health,

Commitments, Contingent Liabili

Commitments, Contingent Liabilities and Litigation	9 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingent Liabilities and Litigation	6. Commitments, Contingent Liabilities and Litigation Commitments Generic Sourcing Venture with CVS Health Corporation ("CVS Health") In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. In August 2021, we amended our agreement to extend the term through June 2029. We are required to make quarterly payments to CVS Health for the term of the arrangement. Contingencies New York Opioid Stewardship Act In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100 million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. In the second quarter of fiscal year 2022, we paid the State of New York $20 million, our portion of the assessment for calendar year 2017. At June 30, 2022, we had an accrual of $20 million, which represented our estimate of our portion of the assessment for calendar year 2018. Du ring the nine months ended March 31, 2023, we recorded $6 million of income to reduce this accrual to the invoiced amount for the calendar year 2018 assessment and we paid $7 million, resulting in an accrual of $7 million at March 31, 2023. Legal Proceedings We become involved from time to time in disputes, litigation and regulatory matters. From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits. From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions. We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government. We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates. We recognize income from the favorable outcome of litigation when we receive the associated cash or assets. We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges, net in our condensed consolidated statements of earnings/(loss); however, losses and recoveries of lost profits from disputes that occur in the ordinary course of business are included within segment profit. For example, in the second quarter of fiscal year 2022, our Pharmaceutical segment profit was positively impacted by a $16 million judgment for lost profits related to an ordinary course intellectual property rights claim. Opioid Lawsuits and Investigations States & Political Subdivisions National Settlement As previously disclosed, in February 2022, we along with two other national distributors (collectively, the "Distributors") independently approved a settlement and settlement agreement (the "Settlement Agreement") to settle the vast majority of opioid lawsuits and claims brought by states and political subdivisions. This Settlement Agreement became effective on April 2, 2022. In May and June 2022, the Distributors reached agreements with the States of Washington and Oklahoma, respectively, to resolve the opioid-related claims of those states and their political subdivisions. Under these agreements, Cardinal Health agreed to pay approximately $160 million to the State of Washington and its participating subdivisions and approximately $95 million to the State of Oklahoma and its participating subdivisions. These amounts are consistent with the amounts that would have been allocated to Washington and Oklahoma under the Settlement Agreement. Each of Washington and Oklahoma is now subject to the Settlement Agreement. In addition to the Distributors, parties to the Settlement Agreement include 48 states, the District of Columbia and 5 U.S. territories. Over 99 percent of political subdivisions (by population as calculated under the Settlement Agreement) that had brought opioid-related suits against us have chosen to join the Settlement Agreement or have had their claims addressed by state legislation. Under the Settlement Agreement, we agreed to pay up to approximately $6.3 billion over 18 years. The Settlement Agreement also includes injunctive relief terms related to distributors’ controlled substance anti-diversion programs. For more information on the terms of the Settlement Agreement, refer to our 2022 Form 10-K. As a result of the Settlement Agreement, most lawsuits brought against us by states and other political subdivisions have been dismissed. We continue to engage in resolution discussions with certain non-participating political subdivisions, including the Attorney General for the State of Alabama, and we intend to defend ourselves vigorously against all remaining lawsuits. During the nine months ended March 31, 2023, we made our second annual payment of $372 million under the Settlement Agreement. In total, we have $5.85 billion accrued at March 31, 2023, of which $437 million is included in other accrued liabilities and the remainder is included in deferred income taxes and other liabilities in our condensed consolidated balance sheets. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and none of these agreements is an admission of liability or wrongdoing. Other Settlements West Virginia subdivisions and Native American tribes were not a part of the national settlement, and we had separate negotiations with these groups. A bench trial before a federal judge in West Virginia in a case brought by Cabell County and City of Huntington against the Distributors concluded in July 2021. In July 2022, a judgment in favor of the Distributors was entered. In July 2022, the Distributors reached an agreement to settle the opioid-related claims of the majority of the remaining West Virginia subdivisions. Under this agreement, we have agreed to pay eligible West Virginia subdivisions up to approximately $124 million over an eleven-year period. This agreement became effective in October 2022 when all participating subdivisions dismissed their cases. In October 2022, we executed a final settlement agreement with the Native American Tribes, pursuant to which we will pay up to approximately $136 million over five years. In connection with this settlement, the court entered dismissals for the Native American tribes' cases. Department of Justice Investigations We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these investigations. We are unable to predict the outcome of any of these investigations. Private Plaintiffs The Settlement Agreement does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals alleging personal injury. Private parties had brought approximately 457 lawsuits as of April 28, 2023. Of these, 107 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. A trial in a case involving 21 plaintiffs began in state court in Georgia in January 2023 and concluded in March 2023 with a verdict for the company and other defendants on all claims. The plaintiffs' motion for a new trial is pending. A trial involving eight hospital plaintiffs is scheduled to begin in Alabama in July 2023. We are vigorously defending ourselves in all of these matters; however, trials are inherently unpredictable and it is possible that an unfavorable outcome in these matters, individually or in the aggregate, could have a negative impact on our financial results. Insurance Litigation We are involved in ongoing legal proceedings with insurers related their obligations to reimburse us for defense and indemnity costs in connection with the lawsuits described above. In the nine months ended March 31, 2023, we received approximately $10 million in insurance recoveries related to these matters; however, we have not recorded a receivable for any additional recoveries as of March 31, 2023. Cordis IVC Filter Matters Product Liability Lawsuits We have been named as a defendant in approximately 453 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,171 plaintiffs that allege personal injuries associated with the use of IVC filter products. These lawsuits sought a variety of remedies, including unspecified monetary damages. The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained. In April 2023, we executed a settlement agreement that, if certain conditions are satisfied, will resolve approximately 4,376 claims for $275 million. This settlement agreement is subject to certain conditions, including certain opt-in thresholds. Between May and September 2023, we will make settlement payments totaling $275 million into a qualified settlement fund, which will be disbursed to the plaintiffs if required conditions are satisfied. Since July 2021, we have also entered into other agreements to settle approximately 2,881 product liability claims. These settlements will not resolve all IVC filter product liability claims and we will continue to vigorously defend ourselves in the remaining lawsuits. Additionally, in August 2021, the Attorney General for the State of New Mexico filed an action against certain IVC filter manufacturers, including us, alleging claims under New Mexico's Unfair Practices Act, Medicaid Fraud Act and Fraud Against Taxpayers Act. The allegations are similar to those made in the product liability lawsuits. We recognized income of $71 million and $95 million during the three and nine months ended March 31, 2023, respectively, primarily related to a reduction of the reserve for the estimated settlement and defense costs for these matters due to the execution of the settlements noted above. At March 31, 2023, we had a total of $385 million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits in our condensed consolidated balance sheets. Shareholder Securities Litigation In August 2019, the Louisiana Sheriffs' Pension & Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition and integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In February 2023, we reached an agreement in principle with the plaintiffs to settle this matter for $109 million, subject to final approval by the court. The court granted its preliminary approval in April 2023 and will conduct a final hearing in September 2023. If the settlement is approved, our insurance carriers will pay $109 million to the plaintiffs. Other Civil Litigation Generic Pharmaceutical Pricing Antitrust Litigation In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. In May 2020, the court granted our motion to dismiss. In July 2022, the indirect purchasers filed an amended complaint and in August 2022, we filed a motion to dismiss the intended complaint. We are vigorously defending ourselves in this matter. Antitrust Litigation Proceeds In October 2022, we received net cash proceeds resulting from the settlement of a lawsuit in which we were a class member or plaintiff of $66 million, which was recognized in litigation (recoveries)/charges, net, during the nine months ended March 31, 2023. Shareholder Derivative Litigation Between June 2019 and January 2020, three purported shareholders filed actions on behalf of Cardinal Health, Inc. in the U.S. District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation. In January 2020, the court consolidated these derivative cases under the caption In re Cardinal Health, Inc. Derivative Litigation and in March 2020, plaintiffs filed an amended complaint.

Income Taxes

Income Taxes	9 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	7. Income Taxes Fluctuations in our provision for income taxes as a percentage of pre-tax earnings/(loss) (“effective tax rate”) are due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. Effective Tax Rate During the three and nine months ended March 31, 2023, the effective tax rate was 36.3 percent and 36.7 percent, respectively, and reflects any impact of the tax effects of the goodwill impairment charges recognized during the three and nine months ended March 31, 2023. During the three and nine months ended March 31, 2022, the effective tax rate was (916.5) percent and (44.4) percent, respectively, and reflects the impact of the tax effect of the goodwill impairment charges recognized during the three and nine months ended March 31, 2022. Tax Effects of Goodwill Impairment Charges During the nine months ended March 31, 2023, we recognized pre-tax goodwill impairment charges of $863 million related to the Medical Unit. The net tax benefit related to these charges is $68 million for fiscal 2023. Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our impact from income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur. The tax effect of the goodwill impairment charges during the nine months ended March 31, 2023 was included in our estimated annual effective tax rate because it was not considered unusual or infrequent, given that we recorded goodwill impairments in prior fiscal years. The impact of the non-deductible goodwill increased the estimated annual effective tax rate for fiscal 2023. Applying the higher tax rate to the pre-tax income for the nine months ended March 31, 2023 resulted in recognizing an incremental interim tax expense of approximately $74 million, which impacted the provision for income taxes in the condensed consolidated statements of earnings/(loss) during the three months ended March 31, 2023 and prepaid expenses and other assets in the condensed consolidated balance sheet at March 31, 2023. The incremental interim tax benefit recognized during the nine months ended March 31, 2023 was $66 million and will reverse in the fourth quarter of fiscal 2023. Unrecognized Tax Benefits We had $1.1 billion and $943 million of unrecognized tax benefits, at March 31, 2023 and June 30, 2022, respectively. The March 31, 2023 and June 30, 2022 balances include $897 million and $858 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. At March 31, 2023 and June 30, 2022, we had $61 million and $48 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of up to $125 million, exclusive of penalties and interest. Other Tax Matters We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2015 through the current fiscal year. We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $80 million and $75 million at

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Disclosures	8. Fair Value Measurements The following tables present the fair values for assets and (liabilities) measured on a recurring basis at: March 31, 2023 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 1,302 $ — $ — $ 1,302 Other investments (1) 95 — — 95 Liabilities: Forward contracts (2) — (52) — (52) June 30, 2022 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 2,425 $ — $ — $ 2,425 Other investments (1) 97 — — 97 Forward contracts (2) — 15 — 15 (1) The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices. (2) The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.

Financial Instruments

Financial Instruments	9 Months Ended
	Mar. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	9. Financial Instruments We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements. Interest Rate Risk Management We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities on our fixed-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs. Currency Exchange Risk Management We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses. Commodity Price Risk Management We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases. Fair Value Hedges We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of earnings/(loss). For the three and nine months ended March 31, 2023 and 2022, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt. During the nine months ended March 31, 2023 and 2022, we entered into pay-floating interest rate swaps with total notional amounts of $200 million and $300 million, respectively. These swaps have been designated as fair value hedges of our fixed rate debt and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. Cash Flow Hedges We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings. Pre-tax gains recognized in other comprehensive income/(loss) were $2 million and $1 million for the three months ended March 31, 2023 and 2022, respectively, and $4 million for both the nine months ended March 31, 2023 and 2022. Gains recognized in accumulated other comprehensive loss and reclassified into earnings were $4 million and immaterial for the three months ended March 31, 2023 and 2022, respectively, and were $8 million and immaterial for the nine months ended March 31, 2023 and 2022, respectively. Gains currently included within accumulated other comprehensive loss associated with our cash flow hedges to be reclassified into net earnings within the next 12 months are $7 million. Net Investment Hedges We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments. During the three months ended March 31, 2023, we entered into ¥19 billion ($150 million) cross-currency swaps maturing in September 2025, ¥19 billion ($150 million) cross-currency swaps maturing in June 2027, €100 million ($107 million) cross-currency swaps maturing in March 2025 and €100 million ($107 million) cross-currency swaps maturing in March 2026. During the three months ended March 31, 2023, we terminated the ¥48 billion ($400 million) cross-currency swaps entered into in March 2022 and the €200 million ($233 million) cross-currency swap entered into in September 2018 and received net settlements of $10 million and $19 million in cash, respectively, recorded in proceeds from net investment hedge terminations in our condensed consolidated statements of cash flows. Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings. Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was an immaterial loss and a $22 million gain during the three months ended March 31, 2023 and 2022, respectively, and a $21 million loss and a $44 million gain during the nine months ended March 31, 2023 and 2022, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $4 million and $5 million during the three months ended March 31, 2023 and 2022, respectively, and $12 million and $16 million during the nine months ended March 31, 2023 and 2022, respectively. Economic (Non-Designated) Hedges We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded an immaterial loss and a $4 million loss during the three months ended March 31, 2023 and 2022, respectively, and a $3 million loss and an immaterial loss during the nine months ended March 31, 2023 and 2022, respectively. The principal currencies managed through foreign currency contracts are Canadian dollar, Euro, Chinese renminbi, Indian rupee and Thai baht. Fair Value of Financial Instruments The carrying amounts of cash and equivalents, trade receivables, accounts payable and other accrued liabilities at March 31, 2023 and June 30, 2022 approximate fair value due to their short-term maturities. The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at: (in millions) March 31, 2023 June 30, 2022 Estimated fair value $ 4,466 $ 5,049 Carrying amount 4,734 5,315 The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Shareholders' Equity	10. Shareholders' Equity/(Deficit) We repurchased $1.5 billion and $1.0 billion of our common shares, in the aggregate, through share repurchase programs during the nine months ended March 31, 2023 and 2022, respectively. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes. During the three months ended March 31, 2023, we entered into an accelerated share repurchase ("ASR") program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial delivery of 2.6 million common shares using a reference price of $77.03. The program concluded on February 28, 2023 at a volume weighted average price per common share of $77.27 resulting in a final delivery of 0.6 million common shares. During the three months ended December 31, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $250 million. We received an initial delivery of 2.6 million common shares using a reference price of $76.58. The program concluded on January 13, 2023 at a volume weighted average price per common share of $77.50 resulting in a final delivery of 0.6 million common shares. During the three months ended September 30, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $1.0 billion. We received an initial delivery of 12.0 million common shares using a reference price of $66.74. The program concluded on December 23, 2022 at a volume weighted average price per common share of $73.36 resulting in a final delivery of 1.6 million common shares. During the three months ended March 31, 2022, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $200 million. We received an initial delivery of 3.0 million common shares using a reference price of $54.01. The program concluded on April 18, 2022 at a volume weighted average price per common share of $56.02 resulting in a final delivery of 0.6 million common shares. During the three months ended December 31, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $300 million. We received an initial delivery of 4.8 million common shares using a reference price of $50.30. The program concluded on January 31, 2022 at a volume weighted average price per common share of $49.39 resulting in a final delivery of 1.3 million common shares. During the three months ended September 30, 2021, we entered into an ASR program to repurchase common shares for an aggregate purchase price of $500 million. We received an initial delivery of 7.8 million common shares using a reference price of $51.53. The program concluded on October 4, 2021 at a volume weighted average price per common share of $51.10 resulting in a final delivery of 2.0 million common shares. Accumulated Other Comprehensive Loss The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total: (in millions) Foreign Unrealized Accumulated Other Balance at June 30, 2022 $ (102) $ (12) $ (114) Other comprehensive loss, before reclassifications (34) 15 (19) Amounts reclassified to earnings — (9) (9) Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax benefit of $5 million (34) 6 (28) Balance at March 31, 2023 $ (136) $ (6) $ (142) (in millions) Foreign Unrealized Accumulated Other Balance at June 30, 2021 $ (46) $ 12 $ (34) Other comprehensive loss, before reclassifications (47) 9 (38) Amounts reclassified to earnings — (5) (5) Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax benefit of $6 million (47) 4 (43) Balance at March 31, 2022 $ (93) $ 16 $ (77)

Earnings Per Share Attributable

Earnings Per Share Attributable to Cardinal Health, Inc.	9 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	11. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc. The following table reconciles the number of common shares used to compute basic and diluted earnings/(loss) per share attributable to Cardinal Health, Inc.: Three Months Ended March 31, (in millions) 2023 2022 Weighted-average common shares–basic 256 275 Effect of dilutive securities: Employee stock options, restricted share units and performance share units 2 — Weighted-average common shares–diluted 258 275 Nine Months Ended March 31, (in millions) 2023 2022 Weighted-average common shares–basic 263 281 Effect of dilutive securities: Employee stock options, restricted share units and performance share units 1 — Weighted-average common shares–diluted 264 281 The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were 2 million for both the three and nine months ended March 31, 2023. The potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive were 5 million for both the three and nine months ended March 31, 2022. For the three and nine months ended March 31, 2022, there were 2 million and 1 million potentially dilutive employee stock options, restricted share units and performance share units not included in the computation of diluted loss per common share attributable to Cardinal Health, Inc. because their effect would have been antidilutive as a result of the net loss during those periods.

Segment Information

Segment Information	9 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Segment Information	12. Segment Information Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities. Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; provides pharmacy management services to hospitals and operates a limited number of pharmacies, including pharmacies in community health centers; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and connects pharmacists, payers and pharmaceutical companies and delivers health solutions for medication therapy management, digital patient engagement and telepharmacy; and repackages generic pharmaceuticals and over-the-counter healthcare products. Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of medical, surgical and laboratory products known as national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division. Revenue The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate: Three Months Ended March 31, (in millions) 2023 2022 Pharmaceutical Distribution and Specialty Solutions (1) (2) $ 46,497 $ 40,723 Nuclear and Precision Health Solutions (3) 312 234 Pharmaceutical segment revenue 46,809 40,957 Medical distribution and products (4) 3,034 3,283 Cardinal Health at-Home Solutions 650 601 Medical segment revenue 3,684 3,884 Total segment revenue 50,493 44,841 Corporate (5) (6) (5) Total revenue $ 50,487 $ 44,836 Nine Months Ended March 31, (in millions) 2023 2022 Pharmaceutical Distribution and Specialty Solutions (1) (2) $ 139,435 $ 121,501 Nuclear and Precision Health Solutions (3) 875 653 Pharmaceutical segment revenue 140,310 122,154 Medical distribution and products (4) 9,273 10,296 Cardinal Health at-Home Solutions 1,986 1,822 Medical segment revenue 11,259 12,118 Total segment revenue 151,569 134,272 Corporate (5) (10) (11) Total revenue $ 151,559 $ 134,261 (1) Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services." (2) Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division. (3) Increase from prior year relates to new product launches and changes in revenue recognition presentation from agent to principal for certain customer contracts. (4) Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division. (5) Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments. The following tables present revenue by geographic area: Three Months Ended March 31, (in millions) 2023 2022 United States $ 49,326 $ 43,710 International 1,167 1,131 Total segment revenue 50,493 44,841 Corporate (1) (6) (5) Total revenue $ 50,487 $ 44,836 Nine Months Ended March 31, (in millions) 2023 2022 United States $ 148,136 $ 130,933 International 3,433 3,339 Total segment revenue 151,569 134,272 Corporate (1) (10) (11) Total revenue $ 151,559 $ 134,261 (1) Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments. Segment Profit We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&A") expenses. Segment SG&A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial and customer care shared services, human resources, information technology and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit. We do not allocate the following items to our segments: • last-in first-out, or ("LIFO"), inventory charges/(credits); • surgical gown recall costs/(income); • shareholder cooperation agreement costs; • state opioid assessment related to prior fiscal years; • restructuring and employee severance; • amortization and other acquisition-related costs; • impairments and (gain)/loss on disposal of assets, net; in connection with goodwill impairment testing for the Medical Unit as discussed further in Note 4 , we recognized cumulative goodwill impairment charges of $863 million during the nine months ended March 31, 2023; • litigation (recoveries)/charges, net; • other (income)/expense, net; • interest expense, net; • loss on early extinguishment of debt; • (gain)/loss on sale of equity interest in naviHealth; or • provision for income taxes In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $9 million and $20 million for the three months ended March 31, 2023 and 2022, and $20 million and $38 million for the nine months ended March 31, 2023 and 2022, respectively. The following tables present segment profit by reportable segment and Corporate: Three Months Ended March 31, (in millions) 2023 2022 Pharmaceutical (1) $ 600 $ 487 Medical 20 59 Total segment profit 620 546 Corporate (48) (643) Total operating earnings/(loss) $ 572 $ (97) Nine Months Ended March 31, (in millions) 2023 2022 Pharmaceutical (1) $ 1,495 $ 1,319 Medical 29 232 Total segment profit 1,524 1,551 Corporate (934) (2,183) Total operating earnings/(loss) $ 590 $ (632) (1) Pharmaceutical segment profit includes opioid-related litigation defense and compliance costs, but does not include a one-time contingent attorney fee of $18 million incurred during the three and nine months ended March 31, 2022 related to the finalization of the Settlement Agreement. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this related fee was included in litigation (recoveries)/charges, net in the condensed consolidated statements of earnings/(loss). Additionally, pharmaceutical segment profit during the nine months ended March 31, 2022 was positively impacted by a $16 million judgment for lost profits related to an ordinary course intellectual property rights claim. The following table presents total assets for each reportable segment and Corporate at: (in millions) March 31, June 30, Pharmaceutical $ 27,954 $ 26,409 Medical (1) 10,544 11,632 Corporate 4,879 5,837 Total assets $ 43,377 $ 43,878

Share-Based Compensation

Share-Based Compensation	3 Months Ended
	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	13. Share-Based Compensation We maintain stock incentive plans (collectively, the “Plans”) for the benefit of certain of our officers, directors and employees. The following table provides total share-based compensation expense by type of award: Three Months Ended March 31, (in millions) 2023 2022 Restricted share unit expense $ 17 $ 18 Performance share unit expense 4 5 Total share-based compensation $ 21 $ 23 Nine Months Ended March 31, (in millions) 2023 2022 Restricted share unit expense $ 49 $ 53 Performance share unit expense 20 12 Total share-based compensation $ 69 $ 65 The total tax benefit related to share-based compensation was $3 million for both the three months ended March 31, 2023 and 2022, and $9 million for both the nine months ended March 31, 2023 and 2022. Restricted Share Units Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards. The following table summarizes all transactions related to restricted share units under the Plans: (in millions, except per share amounts) Restricted Share Units Weighted-Average Nonvested at June 30, 2022 2.7 $ 46.03 Granted 1.3 70.26 Vested (1.3) 50.03 Canceled and forfeited (0.5) 58.30 Nonvested at March 31, 2023 2.2 $ 57.14 At March 31, 2023, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $87 million, which is expected to be recognized over a weighted-average period of two years. Performance Share Units Performance share units vest over a 3-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 234 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards. The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts): (in millions, except per share amounts) Performance Weighted-Average Nonvested at June 30, 2022 1.2 $ 54.32 Granted 0.6 70.52 Vested (0.4) 59.04 Canceled and forfeited (0.3) 65.59 Nonvested at March 31, 2023 1.1 $ 76.24 At March 31, 2023, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $39 million, which is expected to be recognized over a weighted-average period of two years if performance goals are achieved.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Recent Financial Accounting Standards	Recently Issued Financial Accounting Standards Not Yet Adopted We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements. Recently Adopted Financial Accounting Standards There were no new material accounting standards adopted during the nine months ended March 31, 2023.
Basis of Presentation	Basis of Presentation Our condensed consolidated financial statements include the accounts of all majority-owned or consolidated subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the condensed consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively. References to "we," "our," and similar pronouns in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or consolidated subsidiaries unless the context requires otherwise. Our fiscal year ends on June 30. References to fiscal 2023 and 2022 in these condensed consolidated financial statements are to the fiscal years ending or ended June 30, 2023 and June 30, 2022, respectively. Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature. In addition, financial results presented for this fiscal 2023 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2023. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 (our "2022 Form 10-K"). Recently Issued Financial Accounting Standards Not Yet Adopted We assess the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board ("FASB") on our condensed consolidated financial statements as well as material updates to previous assessments, if any, from our fiscal 2022 Form 10-K. There were no accounting standards issued in fiscal 2023 that will have a material impact on our condensed consolidated financial statements. Recently Adopted Financial Accounting Standards There were no new material accounting standards adopted during the nine months ended March 31, 2023.

Restructuring and Employee Se_2

Restructuring and Employee Severance (Tables)	9 Months Ended
	Mar. 31, 2023
Restructuring Charges [Abstract]
Summary of Restructuring and Employee Severance	The following table summarizes restructuring and employee severance: Three Months Ended March 31, (in millions) 2023 2022 Employee-related $ 3 $ 12 Facility exit and other 13 19 Total restructuring and employee severance $ 16 $ 31 Nine Months Ended March 31, (in millions) 2023 2022 Employee-related $ 32 $ 22 Facility exit and other 30 34 Total restructuring and employee severance $ 62 $ 56
Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance	The following table summarizes activity related to liabilities associated with restructuring and employee severance: (in millions) Employee- Facility Exit Total Balance at June 30, 2022 $ 56 $ 10 $ 66 Additions 29 8 37 Payments and other adjustments (36) (15) (51) Balance at March 31, 2023 $ 49 $ 3 $ 52

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	9 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill by Reportable Segment	The following table summarizes the changes in the carrying amount of goodwill by segment and in total: (in millions) Pharmaceutical Medical (1) Total Balance at June 30, 2022 $ 2,673 $ 3,182 $ 5,855 Goodwill acquired, net of purchase price adjustments — 13 13 Foreign currency translation adjustments and other — (5) (5) Goodwill impairment — (863) (863) Balance at March 31, 2023 $ 2,673 $ 2,327 $ 5,000 (1) At March 31, 2023 and June 30, 2022, the Medical segment accumulated goodwill impairment loss was $4.4 billion and $3.5 billion, respectively.
Schedule of Finite-Lived Intangible Assets	The following tables summarize other intangible assets by class at: March 31, 2023 (in millions) Gross Accumulated Net Weighted- Average Remaining Amortization Period (Years) Indefinite-life intangibles: Trademarks and patents $ 11 $ — $ 11 N/A Total indefinite-life intangibles 11 — 11 N/A Definite-life intangibles: Customer relationships 3,235 2,267 968 10 Trademarks, trade names and patents 550 376 174 9 Developed technology and other 1,037 623 414 9 Total definite-life intangibles 4,822 3,266 1,556 10 Total other intangible assets $ 4,833 $ 3,266 $ 1,567 N/A June 30, 2022 (in millions) Gross Accumulated Net Indefinite-life intangibles: Trademarks and patents $ 11 $ — $ 11 Total indefinite-life intangibles 11 — 11 Definite-life intangibles: Customer relationships 3,272 2,165 1,107 Trademarks, trade names and patents 552 360 192 Developed technology and other 1,038 574 464 Total definite-life intangibles 4,862 3,099 1,763 Total other intangible assets $ 4,873 $ 3,099 $ 1,774

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables present the fair values for assets and (liabilities) measured on a recurring basis at: March 31, 2023 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 1,302 $ — $ — $ 1,302 Other investments (1) 95 — — 95 Liabilities: Forward contracts (2) — (52) — (52) June 30, 2022 (in millions) Level 1 Level 2 Level 3 Total Assets: Cash equivalents $ 2,425 $ — $ — $ 2,425 Other investments (1) 97 — — 97 Forward contracts (2) — 15 — 15 (1) The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices. (2) The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Mar. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount	The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at: (in millions) March 31, 2023 June 30, 2022 Estimated fair value $ 4,466 $ 5,049 Carrying amount 4,734 5,315

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	9 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total	The following tables summarize the changes in the balance of accumulated other comprehensive loss by component and in total: (in millions) Foreign Unrealized Accumulated Other Balance at June 30, 2022 $ (102) $ (12) $ (114) Other comprehensive loss, before reclassifications (34) 15 (19) Amounts reclassified to earnings — (9) (9) Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax benefit of $5 million (34) 6 (28) Balance at March 31, 2023 $ (136) $ (6) $ (142) (in millions) Foreign Unrealized Accumulated Other Balance at June 30, 2021 $ (46) $ 12 $ (34) Other comprehensive loss, before reclassifications (47) 9 (38) Amounts reclassified to earnings — (5) (5) Total other comprehensive loss attributable to Cardinal Health, Inc. net of tax benefit of $6 million (47) 4 (43) Balance at March 31, 2022 $ (93) $ 16 $ (77)

Earnings Per Share Attributab_2

Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)	9 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share	The following table reconciles the number of common shares used to compute basic and diluted earnings/(loss) per share attributable to Cardinal Health, Inc.: Three Months Ended March 31, (in millions) 2023 2022 Weighted-average common shares–basic 256 275 Effect of dilutive securities: Employee stock options, restricted share units and performance share units 2 — Weighted-average common shares–diluted 258 275 Nine Months Ended March 31, (in millions) 2023 2022 Weighted-average common shares–basic 263 281 Effect of dilutive securities: Employee stock options, restricted share units and performance share units 1 — Weighted-average common shares–diluted 264 281

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Disaggregation of Revenue [Table Text Block]	Three Months Ended March 31, (in millions) 2023 2022 Pharmaceutical Distribution and Specialty Solutions (1) (2) $ 46,497 $ 40,723 Nuclear and Precision Health Solutions (3) 312 234 Pharmaceutical segment revenue 46,809 40,957 Medical distribution and products (4) 3,034 3,283 Cardinal Health at-Home Solutions 650 601 Medical segment revenue 3,684 3,884 Total segment revenue 50,493 44,841 Corporate (5) (6) (5) Total revenue $ 50,487 $ 44,836 Nine Months Ended March 31, (in millions) 2023 2022 Pharmaceutical Distribution and Specialty Solutions (1) (2) $ 139,435 $ 121,501 Nuclear and Precision Health Solutions (3) 875 653 Pharmaceutical segment revenue 140,310 122,154 Medical distribution and products (4) 9,273 10,296 Cardinal Health at-Home Solutions 1,986 1,822 Medical segment revenue 11,259 12,118 Total segment revenue 151,569 134,272 Corporate (5) (10) (11) Total revenue $ 151,559 $ 134,261 (1) Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services." (2) Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division. (3) Increase from prior year relates to new product launches and changes in revenue recognition presentation from agent to principal for certain customer contracts. (4) Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division. (5) Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Revenue from External Customers by Geographic Areas [Table Text Block]	The following tables present revenue by geographic area: Three Months Ended March 31, (in millions) 2023 2022 United States $ 49,326 $ 43,710 International 1,167 1,131 Total segment revenue 50,493 44,841 Corporate (1) (6) (5) Total revenue $ 50,487 $ 44,836 Nine Months Ended March 31, (in millions) 2023 2022 United States $ 148,136 $ 130,933 International 3,433 3,339 Total segment revenue 151,569 134,272 Corporate (1) (10) (11) Total revenue $ 151,559 $ 134,261 (1) Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit by Reportable Segment	The following tables present segment profit by reportable segment and Corporate: Three Months Ended March 31, (in millions) 2023 2022 Pharmaceutical (1) $ 600 $ 487 Medical 20 59 Total segment profit 620 546 Corporate (48) (643) Total operating earnings/(loss) $ 572 $ (97) Nine Months Ended March 31, (in millions) 2023 2022 Pharmaceutical (1) $ 1,495 $ 1,319 Medical 29 232 Total segment profit 1,524 1,551 Corporate (934) (2,183) Total operating earnings/(loss) $ 590 $ (632) (1) Pharmaceutical segment profit includes opioid-related litigation defense and compliance costs, but does not include a one-time contingent attorney fee of $18 million incurred during the three and nine months ended March 31, 2022 related to the finalization of the Settlement Agreement. Due to the unique nature and significance of the Settlement Agreement, and the one-time, contingent nature of the fee, this related fee was included in litigation (recoveries)/charges, net in the condensed consolidated statements of earnings/(loss). Additionally, pharmaceutical segment profit during the nine months ended March 31, 2022 was positively impacted by a $16 million judgment for lost profits related to an ordinary course intellectual property rights claim.
Assets by Reportable Segment	The following table presents total assets for each reportable segment and Corporate at: (in millions) March 31, June 30, Pharmaceutical $ 27,954 $ 26,409 Medical (1) 10,544 11,632 Corporate 4,879 5,837 Total assets $ 43,377 $ 43,878

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Total Share-based Compensation Expense by Type of Award	The following table provides total share-based compensation expense by type of award: Three Months Ended March 31, (in millions) 2023 2022 Restricted share unit expense $ 17 $ 18 Performance share unit expense 4 5 Total share-based compensation $ 21 $ 23 Nine Months Ended March 31, (in millions) 2023 2022 Restricted share unit expense $ 49 $ 53 Performance share unit expense 20 12 Total share-based compensation $ 69 $ 65
Schedule of Transactions Related to Restricted Share Units Under the Plans	The following table summarizes all transactions related to restricted share units under the Plans: (in millions, except per share amounts) Restricted Share Units Weighted-Average Nonvested at June 30, 2022 2.7 $ 46.03 Granted 1.3 70.26 Vested (1.3) 50.03 Canceled and forfeited (0.5) 58.30 Nonvested at March 31, 2023 2.2 $ 57.14
Schedule of Transactions Related to Performance Share Units Under the Plans	The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts): (in millions, except per share amounts) Performance Weighted-Average Nonvested at June 30, 2022 1.2 $ 54.32 Granted 0.6 70.52 Vested (0.4) 59.04 Canceled and forfeited (0.3) 65.59 Nonvested at March 31, 2023 1.1 $ 76.24

Discontinued Operations and Dis

Discontinued Operations and Disposal Groups (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Mar. 31, 2023	Mar. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestitures, net of cash sold		$ 0	$ 923
Cordis Divestiture
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestitures, net of cash sold	$ 923

Restructuring and Employee Se_3

Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Restructuring Charges [Abstract]
Employee-related costs	$ 3	$ 12	$ 32	$ 22
Facility Exit and Other Costs	13	19	30	34
Total restructuring and employee severance	$ 16	$ 31	$ 62	$ 56

Restructuring and Employee Se_4

Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details) $ in Millions	9 Months Ended
	Mar. 31, 2023 USD ($)
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 66
Additions	37
Payments and other adjustments	(51)
Ending Balance	52
Employee- Related Costs
Restructuring Reserve [Roll Forward]
Beginning Balance	56
Additions	29
Payments and other adjustments	(36)
Ending Balance	49
Facility Exit and Other Costs
Restructuring Reserve [Roll Forward]
Beginning Balance	10
Additions	8
Payments and other adjustments	(15)
Ending Balance	$ 3

Restructuring and Employee Se_5

Restructuring and Employee Severance Narative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Restructuring Cost and Reserve [Line Items]
Employee-related costs	$ 3	$ 12	$ 32	$ 22
Facility Exit and Other Costs	$ 13	$ 19	$ 30	$ 34

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2023	Jun. 30, 2022
Goodwill [Roll Forward]
Beginning balance		$ 5,855	$ 5,855
Goodwill acquired, net of purchase price adjustments			13
Foreign currency translation adjustments and other			5
Goodwill impairment			863
Ending balance			5,000
Pharmaceutical
Goodwill [Roll Forward]
Beginning balance		2,673	2,673
Goodwill acquired, net of purchase price adjustments			0
Foreign currency translation adjustments and other			0
Goodwill impairment			0
Ending balance			2,673
Medical
Goodwill [Roll Forward]
Beginning balance		3,182	3,182
Goodwill acquired, net of purchase price adjustments			13
Foreign currency translation adjustments and other			5
Goodwill impairment	$ 709	$ 154	863
Ending balance			2,327
Goodwill, Impaired, Accumulated Impairment Loss			$ 4,400	$ 3,500

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($) $ in Millions	Mar. 31, 2023	Jun. 30, 2022
Indefinite-lived Intangible Assets [Line Items]
Net Intangible	$ 11	$ 11
Finite-Lived Intangible Assets [Line Items]
Gross Intangible	4,822	4,862
Accumulated Amortization	3,266	3,099
Net Intangible	$ 1,556	1,763
Weighted- Average Remaining Amortization Period (Years)	10 years
Gross Intangible, Total other intangible assets	$ 4,833	4,873
Net Intangible, Total other intangible assets	1,567	1,774
Trademarks and patents
Indefinite-lived Intangible Assets [Line Items]
Net Intangible	11	11
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Intangible	3,235	3,272
Accumulated Amortization	2,267	2,165
Net Intangible	$ 968	1,107
Weighted- Average Remaining Amortization Period (Years)	10 years
Trademarks, trade names and patents
Finite-Lived Intangible Assets [Line Items]
Gross Intangible	$ 550	552
Accumulated Amortization	376	360
Net Intangible	$ 174	192
Weighted- Average Remaining Amortization Period (Years)	9 years
Developed technology and other
Finite-Lived Intangible Assets [Line Items]
Gross Intangible	$ 1,037	1,038
Accumulated Amortization	623	574
Net Intangible	$ 414	$ 464
Weighted- Average Remaining Amortization Period (Years)	9 years

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended					9 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 69			$ 78		$ 211	$ 235
Estimated annual amortization of intangible assets - Remainder of Fiscal Year	71					71
Estimated annual amortization of intangible assets - Year One	261					261
Estimated annual amortization of intangible assets - Year Two	236					236
Estimated annual amortization of intangible assets - Year Three	209					209
Estimated annual amortization of intangible assets - Year Four	177					177
Goodwill [Line Items]
Goodwill	5,000					5,000		$ 5,855
Goodwill impairment						863
Medical
Goodwill [Line Items]
Goodwill	$ 2,327					2,327		$ 3,182
Goodwill impairment		$ 709	$ 154			863
Medical Unit
Goodwill [Line Items]
Goodwill impairment				$ 474	$ 1,300
Medical Unit
Goodwill [Line Items]
Goodwill impairment						$ 863
Discount Rate, Fair Value Input	10%	10.50%	10.50%			10%
Terminal Growth Rate, Fair Value Input	2%	2%	2%			2%
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount	4%					4%

Long-Term Obligations and Oth_2

Long-Term Obligations and Other Short-Term Borrowings (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Debt Instrument [Line Items]
Total Long-Term and Short-Term Obligations	$ 4,700		$ 4,700		$ 5,300
Accounts Payable	29,600		29,600		$ 27,100
Gain (Loss) on Extinguishment of Debt	0	$ 0	0	$ 10
Commercial Paper [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	2,000		2,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	2,000		2,000
Short Term Credit Facilities Member
Debt Instrument [Line Items]
Other Short-term Borrowings	0		0
2.616% Notes due 2022 [Member]
Debt Instrument [Line Items]
Notes Payable Repurchased				572
Gain (Loss) on Extinguishment of Debt				$ 10
3.2% Notes due 2023
Debt Instrument [Line Items]
Repayments of Notes Payable	550
Committed Receivables Sales Facility Program [Member] | Short Term Credit Facilities Member
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 1,000		$ 1,000

Long-Term Obligations and Oth_3

Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details) - USD ($) $ in Millions	9 Months Ended
	Mar. 31, 2023	Jun. 30, 2022
Debt Instrument [Line Items]
Total Long-Term and Short-Term Obligations	$ 4,700	$ 5,300
Long-term Debt and Lease Obligation, Current	26	580
Long-term Debt and Lease Obligation	4,708	$ 4,735
Line of Credit Facility, Average Outstanding Amount	4
Committed Receivables Sales Facility Program [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Amount Outstanding During Period	$ 445

Commitments, Contingent Liabi_2

Commitments, Contingent Liabilities and Litigation (Details) $ in Thousands

3 Months Ended

5 Months Ended

9 Months Ended

22 Months Ended

Jul. 01, 2023 plaintiff

Apr. 30, 2023 lawsuit

Apr. 28, 2023 lawsuit plaintiff

Jul. 31, 2014

Mar. 31, 2023 USD ($) plaintiff

Mar. 31, 2022 USD ($)

Dec. 31, 2021 USD ($)

Sep. 30, 2023 USD ($)

Mar. 31, 2023 USD ($)

Mar. 31, 2022 USD ($)

Apr. 28, 2023 lawsuit

Jan. 31, 2023 numberOfUSTerritories states

Oct. 31, 2022 USD ($)

Jul. 31, 2022 USD ($)

Jun. 30, 2022 USD ($)

Apr. 30, 2018 USD ($)

Loss Contingencies [Line Items]

Gain (Loss) Related to Litigation Settlement

$ 76,000

$ (61,000)

$ 256,000

$ (113,000)

Income from Settlements of Class Action Lawsuits

66,000

Pharmaceutical

Loss Contingencies [Line Items]

Judgment for lost profits

$ 16,000

Product Liability Lawsuits | Subsequent Event

Loss Contingencies [Line Items]

Loss Contingency, Pending Claims, Number | lawsuit

453

453

Product Liability Lawsuits | Subsequent Event | IVC April 2023 Agreement

Loss Contingencies [Line Items]

Loss Contingency, Claims Settled, Number | lawsuit

4,376

Product Liability Lawsuits | Subsequent Event | Other Agreements [Member]

Loss Contingencies [Line Items]

Loss Contingency, Claims Settled, Number | lawsuit

2,881

Product Liability Lawsuits | Minimum

Loss Contingencies [Line Items]

Loss Contingency Accrual

385,000

385,000

Total Opioid Litigation [Member]

Loss Contingencies [Line Items]

Loss Contingency, Estimate of Possible Loss

6,300,000

6,300,000

Settling States | states

48

Settling U.S Territories | numberOfUSTerritories

5

Estimated Litigation Liability

5,850,000

5,850,000

Estimated Litigation Liability, Current

437,000

437,000

New York Opioid Stewardship Act [Member]

Loss Contingencies [Line Items]

Aggregate Annual Assessment

$ 100,000

Loss Contingency Accrual, Payments

$ 20,000

7,000

Loss Contingency Accrual

$ 7,000

7,000

$ 20,000

Loss Contingency Accrual, Period Increase (Decrease)

6,000

Opioid Lawsuits [Member]

Loss Contingencies [Line Items]

Payments for Legal Settlements

372,000

Insurance Recoveries

10,000

Opioid Lawsuits [Member] | WEST VIRGINIA

Loss Contingencies [Line Items]

Loss Contingency, Estimate of Possible Loss

$ 124,000

Opioid Lawsuits [Member] | WASHINGTON

Loss Contingencies [Line Items]

Loss Contingency, Estimate of Possible Loss

160,000

Opioid Lawsuits [Member] | OKLAHOMA

Loss Contingencies [Line Items]

Loss Contingency, Estimate of Possible Loss

$ 95,000

Opioid Lawsuits [Member] | Native American tribes

Loss Contingencies [Line Items]

Loss Contingency, Estimate of Possible Loss

$ 136,000

Opioid Lawsuits [Member] | Private Parties [Member] | Subsequent Event

Loss Contingencies [Line Items]

Loss Contingency, Lawsuits, Number | lawsuit

457

457

Opioid Lawsuits [Member] | Private Parties [Member] | GEORGIA

Loss Contingencies [Line Items]

Loss Contingency, Number of Plaintiffs | plaintiff

21

Opioid Lawsuits [Member] | Private Parties [Member] | ALABAMA | Subsequent Event

Loss Contingencies [Line Items]

Loss Contingency, Number of Plaintiffs | plaintiff

8

Opioid Lawsuits [Member] | Class Action Lawsuits [Member] | Private Parties [Member] | Subsequent Event

Loss Contingencies [Line Items]

Loss Contingency, Lawsuits, Number | lawsuit

107

107

Product Liability Lawsuits

Loss Contingencies [Line Items]

Product Liability Accrual, Period Expense

$ (71,000)

(95,000)

Product Liability Lawsuits | IVC April 2023 Agreement

Loss Contingencies [Line Items]

Loss Contingency, Estimate of Possible Loss

275,000

275,000

Product Liability Lawsuits | Subsequent Event | IVC April 2023 Agreement

Loss Contingencies [Line Items]

Payments for Legal Settlements

$ 275,000

Product Liability Lawsuits | Alameda County [Member] | Subsequent Event

Loss Contingencies [Line Items]

Loss Contingency, Number of Plaintiffs | plaintiff

5,171

Shareholder Derivative Litigation [Member]

Loss Contingencies [Line Items]

Gross Insurance Settlement Before Attorney Fees

124,000

Legal Fees

31,000

Proceeds from Insurance Settlement, Operating Activities

$ 93,000

Shareholder Securities Litigation [Member]

Loss Contingencies [Line Items]

Insurance Recoveries

109,000

Gain (Loss) Related to Litigation Settlement

$ 109,000

CVS Health

Loss Contingencies [Line Items]

Long-term Purchase Commitment, Period

10 years

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended		12 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Taxes
Effective Income Tax Rate Reconciliation, Percent		36.30%	(916.50%)	36.70%	(44.40%)
Goodwill impairment				$ 863
Income Tax Expense (Benefit)		$ 197	$ 1,253	189	$ 328
Unrecognized tax benefits		1,100		1,100			$ 943
Unrecognized tax benefits that would impact effective tax rate		897		897			858
Unrecognized tax benefits, interest and penalties accrued		61		61			48
Medical Unit
Income Taxes
Goodwill impairment				863
Medical Unit Goodwill Impairment [Member]
Income Taxes
Income Tax Expense (Benefit)		74
Forecast [Member] | Medical Unit Goodwill Impairment [Member]
Income Taxes
Income Tax Expense (Benefit)						$ (68)
Forecast [Member] | Medical Unit Goodwill Impairment [Member] | Subsequent Event
Income Taxes
Income Tax Expense (Benefit)	$ 66
Minimum
Income Taxes
Estimated range of decrease in unrecognized tax benefits within the next 12 months		0		0
Maximum
Income Taxes
Estimated range of decrease in unrecognized tax benefits within the next 12 months		125		125
CareFusion [Member]
Income Taxes
Indemnification Receivable		$ 80		$ 80			$ 75

Fair Value Measurements (Fair V

Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) - Recurring - USD ($) $ in Millions	Mar. 31, 2023	Jun. 30, 2022
Assets:
Cash equivalents	$ 1,302	$ 2,425
Other investments	95	97
Forward Contract	(52)	15
Liabilities:
Forward Contract	(52)	15
Level 1
Assets:
Cash equivalents	1,302	2,425
Other investments	95	97
Forward Contract	0	0
Liabilities:
Forward Contract	0	0
Level 2
Assets:
Cash equivalents	0	0
Other investments	0	0
Forward Contract	(52)	15
Liabilities:
Forward Contract	(52)	15
Level 3
Assets:
Cash equivalents	0	0
Other investments	0	0
Forward Contract	0	0
Liabilities:
Forward Contract	$ 0	$ 0

Financial Instruments (Narrativ

Financial Instruments (Narrative) (Details) € in Millions, ¥ in Millions, $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 JPY (¥)	Mar. 31, 2023 EUR (€)
Derivative [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	$ 0	$ 0	$ 0	$ 0
Proceeds from net investment hedge terminations			29	71
Effective March 2022
Derivative [Line Items]
Proceeds from net investment hedge terminations	10
Effective September 2018
Derivative [Line Items]
Proceeds from net investment hedge terminations	19
Cash Flow Hedging [Member]
Derivative [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax	2	1	4	4
Foreign Exchange Contract [Member]
Derivative [Line Items]
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax		22	21	44
Interest Income (Expense), Nonoperating, Net	4	5	12	16
Cash Flow Hedging [Member] | Foreign Exchange Contract [Member]
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	4		8
Cash Flow Hedging [Member] | Foreign Exchange Contract [Member] | Forecast [Member] | Subsequent Event
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net					$ 7
Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swap
Derivative [Line Items]
Derivative Liability, Notional Amount	200	300	200	$ 300
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | Effective March 2022
Derivative [Line Items]
Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount	400		400			¥ 48,000
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | Effective September 2018
Derivative [Line Items]
Derivatives, Hedge Discontinuances, Termination of Hedging Instrument, Notional Amount	233		233				€ 200
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | September 2025
Derivative [Line Items]
Derivative Asset, Notional Amount	150		150			19,000
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | June 2027
Derivative [Line Items]
Derivative Asset, Notional Amount	150		150			¥ 19,000
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | March 2025
Derivative [Line Items]
Derivative Liability, Notional Amount	107		107				100
Designated as Hedging Instrument | Net Investment Hedging [Member] | Currency Swap [Member] | March 2026
Derivative [Line Items]
Derivative Liability, Notional Amount	$ 107		107				€ 100
Other Nonoperating Income (Expense) [Member] | Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]
Derivative [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net		$ (4)	$ (3)

Financial Instruments Summary o

Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details) - USD ($) $ in Millions	Mar. 31, 2023	Jun. 30, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Carrying Amount of Long-Term and other Short-Term Borrowings	$ 4,734	$ 5,315
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Estimated fair value	$ 4,466	$ 5,049

Shareholders' Equity (Narrative

Shareholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions

2 Months Ended

3 Months Ended

4 Months Ended

6 Months Ended

9 Months Ended

Feb. 28, 2023

Jan. 13, 2023

Dec. 23, 2022

Apr. 18, 2022

Jan. 31, 2022

Oct. 04, 2021

Feb. 28, 2023

Mar. 31, 2023

Jan. 13, 2023

Dec. 31, 2022

Sep. 30, 2022

Mar. 31, 2022

Dec. 31, 2021

Oct. 14, 2021

Sep. 30, 2021

Apr. 18, 2022

Jan. 31, 2022

Dec. 23, 2022

Mar. 31, 2023

Mar. 31, 2022

Class of Stock [Line Items]

Purchase of treasury shares

$ 1,500

$ 1,000

$250 million share repurchase program [Member]

Class of Stock [Line Items]

Purchase of treasury shares

$ 250

$1 billion share repurchase program

Class of Stock [Line Items]

Purchase of treasury shares

$ 1,000

$300 million share repurchase program

Class of Stock [Line Items]

Purchase of treasury shares

$ 300

$500 million share repurchase program [Domain]

Class of Stock [Line Items]

Purchase of treasury shares

$ 500

$200 million

Class of Stock [Line Items]

Purchase of treasury shares

$ 200

Treasury Stock, Common

Class of Stock [Line Items]

Purchase of treasury shares

$ 1,500

$ 1,000

Treasury Stock, Shares, Acquired

(4)

(4)

(20)

(19)

Treasury Stock, Common | $250 million share repurchase program [Member]

Class of Stock [Line Items]

Treasury Stock, Shares, Acquired

(0.6)

(0.6)

(2.6)

(2.6)

Treasury shares acquired, average price per share (in usd per share)

$ 77.27

$ 77.50

$ 76.58

$ 77.03

Treasury Stock, Common | $1 billion share repurchase program

Class of Stock [Line Items]

Treasury Stock, Shares, Acquired

(1.6)

(12)

Treasury shares acquired, average price per share (in usd per share)

$ 66.74

$ 73.36

Treasury Stock, Common | $300 million share repurchase program

Class of Stock [Line Items]

Treasury Stock, Shares, Acquired

(1.3)

(4.8)

Treasury shares acquired, average price per share (in usd per share)

$ 50.30

$ 49.39

Treasury Stock, Common | $500 million share repurchase program [Domain]

Class of Stock [Line Items]

Treasury Stock, Shares, Acquired

(2)

(7.8)

Treasury shares acquired, average price per share (in usd per share)

$ 51.10

$ 51.53

Treasury Stock, Common | $200 million

Class of Stock [Line Items]

Treasury Stock, Shares, Acquired

(0.6)

(3)

Treasury shares acquired, average price per share (in usd per share)

$ 54.01

$ 56.02

Shareholders' Equity (Changes i

Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
AOCI, Net of Tax [Roll Forward]
Balance at beginning of period	$ (2,212)	$ 1,002	$ (706)	$ 1,794
Other Comprehensive Income (Loss), Tax			5	6
Total other comprehensive income/(loss), net of tax	4	8	(28)	(43)
Balance at end of period	(2,218)	(693)	(2,218)	(693)
Foreign Currency Translation Adjustments
AOCI, Net of Tax [Roll Forward]
Balance at beginning of period			(102)	(46)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax			(34)	(47)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax			0	0
Total other comprehensive income/(loss), net of tax			(34)	(47)
Balance at end of period	(136)	(93)	(136)	(93)
Unrealized Gain/(Loss) on Derivatives, net of tax
AOCI, Net of Tax [Roll Forward]
Balance at beginning of period			(12)	12
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax			15	9
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax			(9)	(5)
Total other comprehensive income/(loss), net of tax			6	4
Balance at end of period	(6)	16	(6)	16
Accumulated Other Comprehensive Loss
AOCI, Net of Tax [Roll Forward]
Balance at beginning of period			(114)	(34)
Total other comprehensive income/(loss), net of tax			(28)	(43)
Balance at end of period	(142)	(77)	(142)	(77)
AOCI Attributable to Parent
AOCI, Net of Tax [Roll Forward]
Balance at beginning of period	(146)	(85)	(114)	(34)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax			(19)	(38)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax			(9)	(5)
Balance at end of period	$ (142)	$ (77)	$ (142)	$ (77)

Earnings Per Share Attributab_3

Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) shares in Millions, Reportable_Segments in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023 shares	Mar. 31, 2022 Reportable_Segments shares	Mar. 31, 2023 shares	Mar. 31, 2022 Reportable_Segments shares
Earnings Per Share [Abstract]
Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares) | shares	2	5	2	5
Shares that would be antidilutive as a result of net loss | Reportable_Segments		2		1

Earnings Per Share Attributab_4

Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Earnings Per Share [Abstract]
Weighted-average common shares–basic (in shares)	256	275	263	281
Effect of dilutive securities:
Employee stock options, restricted share units, and performance share units (in shares)	2	0	1	0
Weighted-average common shares–diluted (in shares)	258	275	264	281

Segment Information (Narrative)

Segment Information (Narrative) (Details) $ in Millions	3 Months Ended				9 Months Ended
	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2023 USD ($) segment	Mar. 31, 2022 USD ($)
Segment Reporting Information [Line Items]
Loss Related to Litigation Settlement	$ (76)			$ 61	$ (256)	$ 113
Project costs on investment and other spending	9			20	$ 20	38
Number of reportable segments | segment					2
Number of operating segments | segment					2
Goodwill impairment					$ 863
Number of operating segments | segment					2
Number of reportable segments | segment					2
Project costs on investment and other spending	$ 9			$ 20	$ 20	$ 38
Medical Unit
Segment Reporting Information [Line Items]
Goodwill impairment					863
Medical
Segment Reporting Information [Line Items]
Goodwill impairment		$ 709	$ 154		$ 863

Segment Information (Revenue by

Segment Information (Revenue by Reportable Segment) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting Information [Line Items]
Total revenue	$ 50,487	$ 44,836	$ 151,559	$ 134,261
Operating Segments
Segment Reporting Information [Line Items]
Total revenue	50,493	44,841	151,569	134,272
Operating Segments | Pharmaceutical
Segment Reporting Information [Line Items]
Total revenue	46,809	40,957	140,310	122,154
Operating Segments | Medical
Segment Reporting Information [Line Items]
Total revenue	3,684	3,884	11,259	12,118
Corporate
Segment Reporting Information [Line Items]
Total revenue	(6)	(5)	(10)	(11)
Pharmaceutical Distribution and Specialty [Member] | Operating Segments | Pharmaceutical
Segment Reporting Information [Line Items]
Total revenue	46,497	40,723	139,435	121,501
Nuclear Precision Health Services [Member] | Operating Segments | Pharmaceutical
Segment Reporting Information [Line Items]
Total revenue	312	234	875	653
Medical distribution and products [Member] | Operating Segments | Medical
Segment Reporting Information [Line Items]
Total revenue	3,034	3,283	9,273	10,296
Cardinal Health At Home [Member] | Operating Segments | Medical
Segment Reporting Information [Line Items]
Total revenue	$ 650	$ 601	$ 1,986	$ 1,822

Segment Information (Segment Pr

Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating earnings	$ 572	$ (97)		$ 590	$ (632)
Contingent Attorney Fee		18			18
Pharmaceutical
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Judgment for lost profits			$ 16
Operating Segments
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating earnings	620	546		1,524	1,551
Operating Segments | Pharmaceutical
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating earnings	600	487		1,495	1,319
Operating Segments | Medical
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating earnings	20	59		29	232
Corporate
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating earnings	$ (48)	$ (643)		$ (934)	$ (2,183)

Segment Information Revenue Fro

Segment Information Revenue From External Customers By Geographic Areas (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Segment Revenue from External Customers by Geographic Area [Line Items]
Revenue	$ 50,487	$ 44,836	$ 151,559	$ 134,261
UNITED STATES
Segment Revenue from External Customers by Geographic Area [Line Items]
Revenue	49,326	43,710	148,136	130,933
Non-US [Member]
Segment Revenue from External Customers by Geographic Area [Line Items]
Revenue	1,167	1,131	3,433	3,339
Operating Segments
Segment Revenue from External Customers by Geographic Area [Line Items]
Revenue	50,493	44,841	151,569	134,272
Corporate
Segment Revenue from External Customers by Geographic Area [Line Items]
Revenue	$ (6)	$ (5)	$ (10)	$ (11)

Segment Information (Assets by

Segment Information (Assets by Reportable Segment) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2023	Jun. 30, 2022
Segment Reporting Information [Line Items]
Total assets			$ 43,377	$ 43,878
Goodwill impairment			863
Medical Unit
Segment Reporting Information [Line Items]
Goodwill impairment			863
Pharmaceutical
Segment Reporting Information [Line Items]
Goodwill impairment			0
Medical
Segment Reporting Information [Line Items]
Goodwill impairment	$ 709	$ 154	863
Operating Segments | Pharmaceutical
Segment Reporting Information [Line Items]
Total assets			27,954	26,409
Operating Segments | Medical
Segment Reporting Information [Line Items]
Total assets			10,544	11,632
Corporate
Segment Reporting Information [Line Items]
Total assets			$ 4,879	$ 5,837

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Tax benefit related to share-based compensation	$ 3	$ 3	$ 9	$ 9
Restricted Share Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			3 years
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	87		$ 87
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition			2 years
Performance Share Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting Period in years for Shares			3
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 39		$ 39
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition			2 years
Performance Share Units | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target performance goal (as a percent)			0%
Performance Share Units | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target performance goal (as a percent)			234%

Share-Based Compensation (Sched

Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	$ 21	$ 23	$ 69	$ 65
Restricted Share Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	17	18	49	53
Performance Share Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	$ 4	$ 5	$ 20	$ 12

Share-Based Compensation (Sch_2

Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details) - Restricted Share Units $ / shares in Units, shares in Millions, $ in Millions	9 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	2 years
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $	$ 87
Restricted Share Units
Nonvested at beginning of period (in shares) | shares	2.7
Granted (in shares) | shares	1.3
Vested (in shares) | shares	(1.3)
Canceled and forfeited (in shares) | shares	(0.5)
Nonvested at end of period (in shares) | shares	2.2
Weighted-Average Grant Date Fair Value per Share
Nonvested at beginning of period (in usd per share) | $ / shares	$ 46.03
Granted (in usd per share) | $ / shares	70.26
Vested (in usd per share) | $ / shares	50.03
Canceled and forfeited (in usd per share) | $ / shares	58.30
Nonvested at end of period (in usd per share) | $ / shares	$ 57.14

Share-Based Compensation (Sch_3

Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units $ / shares in Units, shares in Millions, $ in Millions	9 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Performance Share Units
Nonvested at beginning of period (in shares) | shares	1.2
Granted (in shares) | shares	0.6
Vested (in shares) | shares	(0.4)
Canceled and forfeited (in shares) | shares	(0.3)
Nonvested at end of period (in shares) | shares	1.1
Weighted-Average Grant Date Fair Value per Share
Nonvested at beginning of period (in usd per share) | $ / shares	$ 54.32
Granted (in usd per share) | $ / shares	70.52
Vested (in usd per share) | $ / shares	59.04
Canceled and forfeited (in usd per share) | $ / shares	65.59
Nonvested at end of period (in usd per share) | $ / shares	$ 76.24
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $	$ 39
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	2 years